Literature DB >> 22360818

Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving ≤2 years and those surviving ≥5 years after baseline right-sided cardiac catheterization.

Omar Batal1, Omar F Khatib, Raed A Dweik, Jeffrey P Hammel, Kevin McCarthy, Omar A Minai.   

Abstract

Idiopathic pulmonary arterial hypertension (PAH) is usually associated with a poor outcome but the prognosis with other forms of PAH is not well-described. Advances in therapy have furthered clouded the disease course. We sought to determine the baseline indicators of prognosis in patients with PAH. We reviewed the records of patients with PAH followed up at our institution to identify those who died within 2 years (reduced survival group; n = 21) and those who survived >5 years (long survival group; n = 60). The groups were compared for prognostic significance of the baseline clinical parameters. The reduced survival group were older (p = 0.001) and more likely to have scleroderma-associated PAH (p = 0.01), have pericardial effusion (p = 0.01), have a shorter 6-minute walk test (6MWT) distance (p = 0.001), to require oxygen during 6MWT (p = 0.02), have a worse World Health Organization functional class (p <0.001), and have greater serum brain natriuretic peptide levels (p = 0.01). Regression analysis showed age, World Health Organization functional class, 6MWT distance, the need for oxygen during the 6MWT, and renal disease to be independently associated with a poor prognosis. In conclusion, age, PAH etiology, World Health Organization functional class, pericardial effusion, 6MWT distance, the need for oxygen during the 6MWT, and brain natriuretic peptide are predictors of prognosis in patients PAH receiving specific therapy and might help identify a group that could benefit from aggressive upfront therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22360818     DOI: 10.1016/j.amjcard.2012.01.366

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.

Authors:  Adriano R Tonelli; Laith Alkukhun; Vineesha Arelli; José Ramos; Jennie Newman; Kevin McCarthy; Bohdan Pichurko; Omar A Minai; Raed A Dweik
Journal:  Clin Transl Sci       Date:  2013-09-06       Impact factor: 4.689

2.  Pericardial effusion in pulmonary arterial hypertension.

Authors:  Sandeep Sahay; Adriano R Tonelli
Journal:  Pulm Circ       Date:  2013-11-22       Impact factor: 3.017

3.  Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study.

Authors:  Abhishek Gadre; Christian Ghattas; Xiaozhen Han; Xiaofeng Wang; Omar Minai; Kristin B Highland
Journal:  Lung       Date:  2017-06-23       Impact factor: 2.584

4.  Presence and outcomes of kidney disease in patients with pulmonary hypertension.

Authors:  Sankar D Navaneethan; Edgard Wehbe; Gustavo A Heresi; Varun Gaur; Omar A Minai; Susana Arrigain; Joseph V Nally; Jesse D Schold; Mahboob Rahman; Raed A Dweik
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

5.  Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.

Authors:  Omar A Minai; Quyen Nguyen; Srinivas Mummadi; Esteban Walker; Kevin McCarthy; Raed A Dweik
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

6.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year.

Authors:  Erika L Lundgrin; Margaret M Park; Jacqueline Sharp; W H Wilson Tang; James D Thomas; Kewal Asosingh; Suzy A Comhair; Frank P DiFilippo; Donald R Neumann; Laura Davis; Brian B Graham; Rubin M Tuder; Iva Dostanic; Serpil C Erzurum
Journal:  Ann Am Thorac Soc       Date:  2013-02

7.  Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents.

Authors:  Koji Yamamoto; Yutaka Takeda; Yasuko Takeda; Taio Naniwa; Hitomi Narita; Nobuyuki Ohte
Journal:  BMC Res Notes       Date:  2014-06-12

8.  Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls.

Authors:  Adriano R Tonelli; Xiao-Feng Wang; Laith Alkukhun; Qi Zhang; Raed A Dweik; Omar A Minai
Journal:  Physiol Rep       Date:  2014-06-11

Review 9.  Presurgical pulmonary evaluation in renal transplant patients.

Authors:  Sonu Sahni; Ernesto Molmenti; Madhu C Bhaskaran; Nicole Ali; Amit Basu; Arunabh Talwar
Journal:  N Am J Med Sci       Date:  2014-12

10.  Updating clinical endpoint definitions.

Authors:  Paul M Hassoun; Sylvia Nikkho; Erika B Rosenzweig; Gail Moreschi; John Lawrence; John Teeter; Christian Meier; Ardeshir H Ghofrani; Omar Minai; Paula Rinaldi; Evangelos Michelakis; Ronald J Oudiz
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.